MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc., a global leader in medical dermatology, has launched Talk to the Hand, a disease awareness campaign for healthcare providers that highlights the risk factors, symptoms, and physical and emotional impact of chronic hand eczema (CHE) – a debilitating skin condition for which there are currently no FDA approved treatments.1.

。

Chronic hand eczema (CHE) is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year.5,6 CHE is a heterogeneous, fluctuating, inflammatory skin disease with key symptoms of itch and pain.7 Its pathophysiology is characterized by skin barrier dysfunction, skin inflammation, and skin microbiome alterations.7 The condition can have a high psychological, social, and occupational burden.3,8,9 More than 50% of patients with CHE have one or more additional diagnosed subtype.4.

慢性手部湿疹（CHE）被定义为持续三个月以上或一年内复发两次或两次以上的手部湿疹（HE）[5,6]。CHE是一种异质性，波动性，炎症性皮肤病，具有瘙痒和疼痛的关键症状[7]。其病理生理学特征是皮肤屏障功能障碍，皮肤炎症和皮肤微生物组改变[7]。该病可能具有较高的心理，社会和职业负担[3,8,9]。超过50%的CHE患者有一种或多种额外的诊断亚型。

“As a dermatologist, I’ve seen first-hand the impact CHE has on patients. Many patients with moderate-to-severe CHE say holding, or even just touching, everyday objects can be difficult and frustrating,” said Omar Noor, MD, FAAD, Co-Owner of Rao Dermatology. “Our hands are a part of everything we do and who we are — It is essential for healthcare providers to understand that CHE is not just atopic dermatitis of the hands.

“作为一名皮肤科医生，我亲眼目睹了CHE对患者的影响。许多中度至重度CHE患者说，握住甚至仅仅触摸日常物品可能很困难和令人沮丧，”Rao Dermatology联合所有人、FAAD医学博士Omar Noor说。“我们的手是我们所做的一切和我们是谁的一部分-医疗保健提供者必须了解CHE不仅仅是手部特应性皮炎。

We need to recognize the unique challenges of CHE so that we can more effectively diagnose and care for those across the U.S. living with this condition.”.

我们需要认识到CHE的独特挑战，以便我们能够更有效地诊断和护理美国各地患有这种疾病的人。”。

CHE is not an uncommon disease, with a prevalence rate of approximately 4.7%.10 However, it can negatively impact a patient’s quality of life, psychological well-being, daily life, physical functioning and ability to work.2,3 In addition, CHE poses unique physical and psychological challenges, impacting mood and social activities for a significant majority of patients.2,3 Approximately 79% of patients stated CHE had a negative effect on their mood, 2 and 76% reported it affected their social or leisure activities.2 In addition, 38% of patients feel CHE impacts their engagement in activities.2.

CHE不是一种罕见的疾病，患病率约为4.7%[10]。然而，它会对患者的生活质量，心理健康，日常生活，身体机能和工作能力产生负面影响[2,3]。此外，CHE带来了独特的身体和心理挑战，影响了绝大多数患者的情绪和社交活动[2,3]。大约79%的患者表示CHE对他们的情绪有负面影响，2%和76%的患者表示它影响了他们的社交或休闲活动[2]。此外，38%的患者认为CHE影响了他们的活动。

“LEO Pharma is proud to launch the Talk to the Hand campaign as part of our commitment to make a fundamental difference for patients living with skin disease,” said Brian Hilberdink, EVP and President, Region North America, LEO Pharma. “We are committed to improving the standard of care in medical dermatology and patient voice is an essential part of the equation.

。“我们致力于提高医学皮肤病学的护理标准，患者的声音是这个等式的重要组成部分。

Our hope is that this campaign will help healthcare providers more easily recognize and diagnose CHE and provide patients with the answers they need to manage their skin condition and take back their lives.”.

我们希望这项活动将帮助医疗保健提供者更容易识别和诊断CHE，并为患者提供管理皮肤状况和恢复生命所需的答案。”。

The Talk to the Hand campaign highlights the impact to patients and provides illustrations that explain the impact of CHE through www.TalkCHE.com. Healthcare providers can learn more about CHE risk factors and symptoms and stay up to date on the latest CHE news to facilitate better conversations with their patients and help them access information about treatment options..

“与手对话”活动强调了对患者的影响，并通过www.TalkCHE.com提供了解释CHE影响的插图。医疗保健提供者可以了解更多有关CHE风险因素和症状的信息，并及时了解最新的CHE新闻，以促进与患者的更好对话，并帮助他们获得有关治疗方案的信息。。

“We’re excited about LEO Pharma’s the Talk to the Hand campaign to help shed light on the unmet need for the diagnosis and care for patients living with chronic hand eczema,” said Kristin Belleson, President and CEO National Eczema Association (NEA). “We are optimistic that through continued research and heightened awareness, we will find better and faster ways to determine the root cause of CHE to improve patient outcomes.”.

国家湿疹协会（NEA）主席兼首席执行官克里斯汀·贝莱森（KristinBelleson）表示：“我们对利奥制药（LEO Pharma）的“与手对话”活动感到兴奋，该活动旨在帮助人们了解慢性手部湿疹患者的诊断和护理需求尚未得到满足。”。“我们乐观地认为，通过持续的研究和提高认识，我们将找到更好更快的方法来确定CHE的根本原因，以改善患者的预后。”。

About chronic hand eczema

关于慢性手部湿疹

Chronic hand eczema (CHE) is defined as hand eczema (HE) that lasts for more than three months or relapses twice or more within a year.5,6 CHE is one of the most common skin disorders of the hands with a prevalence rate of approximately 4.7%.10 In a substantial number of patients, CHE can develop into a chronic condition.11 CHE is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.7.

慢性手部湿疹（CHE）被定义为持续三个月以上或一年内复发两次或两次以上的手部湿疹（HE）[5,6]。CHE是手部最常见的皮肤病之一，患病率约为4.7%[10]。在相当多的患者中，CHE可发展为慢性病[11]。CHE是一种以瘙痒和疼痛为特征的波动性疾病，患者可能会出现红斑，鳞屑，苔藓化，角化过度，水泡，水肿以及手和手腕上的裂缝。

Several etiologic and morphologic subtypes exist, including irritant contact dermatitis, allergic contact dermatitis, atopic dermatitis, protein contact dermatitis/contact urticaria, hyperkeratotic HE, and recurrent vesicular HE.12

存在几种病因和形态学亚型，包括刺激性接触性皮炎，过敏性接触性皮炎，特应性皮炎，蛋白质接触性皮炎/接触性荨麻疹，角化过度HE和复发性水疱性HE.12

CHE has been shown to cause psychological and functional burdens that impact patient quality of life,13 with approximately 70% of individuals who live with severe CHE admitting to problems in performing everyday activities, and suffering disruption in their daily life due to the condition.14 Furthermore, careers and earning potential have also been shown to be impacted by the burden of living with CHE.15.

CHE已被证明会造成影响患者生活质量的心理和功能负担[13]，大约70%患有严重CHE的人承认在日常活动中存在问题，并且由于这种情况而在日常生活中受到干扰[14]。此外，职业和收入潜力也被证明受到与CHE一起生活的负担的影响。

About LEO Pharma

关于LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities.

利奥制药（LEO Pharma）是一家全球性公司，致力于提高护理标准，造福皮肤病患者及其家人和社会。LEO Pharma成立于1908年，由LEO基金会拥有多数股权。LEO Pharma致力于数十年的研究和开发，以推动皮肤病学的发展。如今，该公司为所有严重疾病提供了广泛的治疗方法。

LEO Pharma is headquartered in Denmark with a global team of 4,200 people, serving millions of patients across the world. In 2023, the company generated net sales of DKK 11.4 billion..

利奥制药（LEO Pharma）总部位于丹麦，拥有4200人的全球团队，为全球数百万患者提供服务。2023年，该公司净销售额为114亿丹麦克朗。。

About the National Eczema Association

关于美国湿疹协会

Founded in 1988, the National Eczema Association (NEA) is a 501(c)(3) nonprofit and the largest patient advocacy organization serving the over 31 million Americans who live with eczema and those who care for them. NEA provides programs and resources to elevate the diverse lived experience of eczema, and help patients and caregivers understand their disease, actively engage in their care, find strength in one another – and improve their lives.

国家湿疹协会（NEA）成立于1988年，是一个501（c）（3）非营利组织，也是最大的患者倡导组织，为3100多万患有湿疹的美国人及其护理人员提供服务。NEA提供项目和资源，以提高湿疹的多样化生活体验，帮助患者和护理人员了解他们的疾病，积极参与护理，找到彼此的力量，并改善他们的生活。

Additionally, NEA advances critical eczema research and partners with key stakeholders to ensure the patient voice is represented and valued in education, care and treatment decision-making. The eczema community is at an exciting juncture, with increased recognition of the seriousness and burden of eczema and a surge in scientific interest and development of new treatments.

此外，NEA推进关键湿疹研究，并与关键利益相关者合作，以确保患者的声音在教育，护理和治疗决策中得到代表和重视。湿疹社区正处于一个令人兴奋的时刻，人们越来越认识到湿疹的严重性和负担，科学兴趣和新疗法的开发激增。

Bolstered by NEA’s strategic plan, Blueprint 2025, we are driving toward the ultimate vision: a world without eczema. Learn more at NationalEczema.org..

在国家能源局2025年蓝图战略计划的支持下，我们正在朝着最终愿景迈进：一个没有湿疹的世界。在NationalEczema.org了解更多信息。。

References

参考文献

Dubin C, Del Duca E, Guttman-Yassky E. Drugs for the Treatment of Chronic Hand Eczema: Successes and Key Challenges. Ther Clin Risk Manag. 2020;16:1319-1332. Erratum in: Ther Clin Risk Manag. 2021 Mar 18;17:233.

Dubin C，Del Duca E，Guttman Yassky E.治疗慢性手部湿疹的药物：成功和关键挑战。临床风险管理。2020年；16： 1319-1332年。勘误表：临床风险管理。2021年3月18日；17： 。

Ahmed A, Shah R, Papadopoulos L, Bewley A. An ethnographic study into the psychological impact and adaptive mechanisms of living with hand eczema. Clin Exp Dermatol. 2015;40(5):495-501.

Ahmed A，Shah R，Papadopoulos L，Bewley A.手部湿疹生活的心理影响和适应机制的人种学研究。临床实验皮肤病。2015年；40（5）：495-501。

Thyssen JP, Silverberg JI, Guttman-Yassky E. Chronic hand eczema understanding has ramifications on clinical management. J Eur Acad Dermatol Venereol. 2020;34(8):e429-e430.

Thyssen JP，Silverberg JI，Guttman Yassky E.慢性手部湿疹的理解对临床管理有影响。J Eur Acad Dermatol Venereol。2020年；。

Agner T, Aalto-Korte K, Andersen KE, et al. Classification of hand eczema. J Eur Acad Dermatol Venereol. 2015;29(12):2417-2422.

Agner T，Aalto Korte K，Andersen KE等。手部湿疹的分类。J Eur Acad Dermatol Venereol。2015年；29（12）：2417-2422。

Lynde C, Guenther L, Diepgen TL, et al. Canadian hand dermatitis management guidelines. J Cutan Med Surg. 2010;14(6):267-284. Erratum in: J Cutan Med Surg. 2011 Nov-Dec;15(6):360.

Lynde C，Guenther L，Diepgen TL等。加拿大手部皮炎管理指南。J Cutan Med Surg。2010；14（6）：267-284。勘误表：J Cutan Med Surg。2011年11月至12月；15（6）：360。

Diepgen TL, Andersen KE, Chosidow O, et al. Guidelines for diagnosis, prevention and treatment of hand eczema. J Dtsch Dermatol Ges. 2015;13(1):e1-e22.

Diepgen TL，Andersen KE，Chosidow O等。手部湿疹的诊断，预防和治疗指南。J Dtsch皮肤病杂志。2015年；13（1）：e1-e22。

Lee GR, Maarouf M, Hendricks AK, Lee DE, Shi VY. Current and emerging therapies for hand eczema. Dermatol Ther. 2019;32(3):e12840.

Lee GR，Maarouf M，Hendricks AK，Lee DE，Shi VY。手部湿疹的当前和新兴疗法。皮肤病。2019年；32（3）：e12840。

Thyssen JP, Schuttelaar MLA, Alfonso JH, et al. Guidelines for diagnosis, prevention, and treatment of hand eczema. Contact Dermatitis. 2022;86(5):357-378.

Thyssen JP，Schuttelaar MLA，Alfonso JH等。手部湿疹的诊断、预防和治疗指南。接触性皮炎。2022年；86（5）：357-378。

Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706.

Grant L，Seiding Larsen L，Burrows K等。基于对患者和专家皮肤科医生的定性访谈，开发慢性手部湿疹（CHE）的概念模型。高级Ther。2020年；37（2）：692-706。

Apfelbacher C, Bewley A, Molin S, et al. Prevalence of Chronic Hand Eczema in adults: A cross-sectional multi-national study of 60,000 respondents in the general population. Presented at the 2024 European Society of Contact Dermatitis (ESCD) congress; September 04-07 2024; Dresden, Germany. Poster presentation #3.

Apfelbacher C，Bewley A，Molin S等。成人慢性手部湿疹的患病率：一项针对60000名普通人群的横断面多国研究。在2024年欧洲接触性皮炎学会（ESCD）大会上发表；；德国德累斯顿。海报展示#3。

Bissonnette R, Diepgen TL, Elsner P, et al. Redefining treatment options in chronic hand eczema (CHE). J Eur Acad Dermatol Venereol. 2010;24 Suppl 3:1-20.

Bissonnette R，Diepgen TL，Elsner P等。重新定义慢性手部湿疹（CHE）的治疗选择。J Eur Acad Dermatol Venereol。2010年；24补充3:1-20。

Thyssen JP, et al. Contact Dermatitis 2022;86:357–378; 3. Diepgen TL, et al. J Dtsch Dermatol Ges 2015;13:e1–22.

Thyssen JP等人，接触性皮炎2022；86:357-378；3.Diepgen TL等人，J DTSCH皮肤病GES 2015；13:E1-22。

Grant L, Seiding Larsen L, Burrows K, et al. Development of a Conceptual Model of Chronic Hand Eczema (CHE) Based on Qualitative Interviews with Patients and Expert Dermatologists. Adv Ther. 2020;37(2):692-706.

Grant L，Seiding Larsen L，Burrows K等。基于对患者和专家皮肤科医生的定性访谈，开发慢性手部湿疹（CHE）的概念模型。高级Ther。2020年；37（2）：692-706。

Cortesi PA, Scalone L, Belisari A, et al. Cost and quality of life in patients with severe chronic hand eczema refractory to standard therapy with topical potent corticosteroids. Contact Dermatitis. 2014;70(3):158-168.

Cortesi PA，Scalone L，Belisari A等。局部强效皮质类固醇标准治疗难治的严重慢性手部湿疹患者的成本和生活质量。接触性皮炎。2014年；70（3）：158-168。

Voorberg AN, Loman L, Schuttelaar MLA. Prevalence and Severity of Hand Eczema in the Dutch General Population: A Cross-sectional, Questionnaire Study within the Lifelines Cohort Study. Acta Derm Venereol. 2022;102:adv00626.

沃伯格·安（Voorberg AN），洛曼·L（Loman L），舒特拉尔（Schuttelaar MLA）。荷兰普通人群手部湿疹的患病率和严重程度：生命线队列研究中的横断面问卷研究。性病学报。2022年；102:adv00626。

MAT-76985 October 2024

MAT-76985 2024年10月